Literature DB >> 11048968

Alendronate-related oral mucosa ulcerations.

M A Gonzalez-Moles1, J V Bagan-Sebastian.   

Abstract

Alendronate is widely used in the treatment of osteoporosis and other bone diseases. Although it is considered a well-tolerated drug, there are numerous reports of adverse effects on the mucosa in the upper aerodigestive tract, with oesophagitis as the most common complication. The strict regulations for the proper administration of the drug indicate that these side effects might well be the result of a direct, irritant mechanism on the upper aerodigestive tract. We present two clinical cases of patients who developed extensive palatal ulcers as a result of taking alendronate. We discuss possible mechanisms implicated in the production of the ulcers and some clinical factors of interest.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11048968     DOI: 10.1034/j.1600-0714.2000.291006.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  14 in total

1.  [Chronic mouth ulcer due to inadequate ingestion of alendronate].

Authors:  Francisco Cardona Tortajada; Esther Sainz Gómez; Jorge Figuerido Garmendia; Ana Lirón de Robles Adsuar
Journal:  Aten Primaria       Date:  2008-08       Impact factor: 1.137

2.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

3.  Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V.

Authors:  Huan Zhou; Joseph G Lawrence; Ahmed H Touny; Sarit B Bhaduri
Journal:  J Mater Sci Mater Med       Date:  2011-12-17       Impact factor: 3.896

4.  Lip ulceration associated with intravenous administration of zoledronic acid: report of a case.

Authors:  Dimitrios Andreadis; Stergios Mauroudis; Athanasios Poulopoulos; Anastasios Markopoulos; Apostolos Epivatianos
Journal:  Head Neck Pathol       Date:  2011-11-22

5.  Bisphosphonates inhibit expression of p63 by oral keratinocytes.

Authors:  E L Scheller; C M Baldwin; S Kuo; N J D'Silva; S E Feinberg; P H Krebsbach; P C Edwards
Journal:  J Dent Res       Date:  2011-05-06       Impact factor: 6.116

6.  Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

Authors:  Arno Wutzl; Gabriela Eisenmenger; Martha Hoffmann; Christian Czerny; Doris Moser; Peter Pietschmann; Rolf Ewers; Arnulf Baumann
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

Review 7.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  M H Abu-Id; Y Açil; J Gottschalk; T Kreusch
Journal:  Mund Kiefer Gesichtschir       Date:  2006-03

8.  Multiple systemic diseases complicated by bisphosphonate osteonecrosis: a case report.

Authors:  Fabrizio Carini; Lorena Barbano; Vito Saggese; Dario Monai; Gianluca Porcaro
Journal:  Ann Stomatol (Roma)       Date:  2012-11-14

9.  The influence of bone mineral density and bisphosphonate therapy on the determinants of oral health and changes on dental panoramic radiographs in postmenopausal women.

Authors:  Olja Grgić; Branka Kovačev-Zavišić; Tanja Veljović; Jovanka Novaković-Paro; Tatjana Maravić; Branislav Bajkin
Journal:  Clin Oral Investig       Date:  2016-03-03       Impact factor: 3.573

10.  Localized IgG4-related disease manifested on the tongue: a case report.

Authors:  Helya Hashemi; Andreas Thor; Erik Hellbacher; Marie Carlson; Miklós Gulyás; Lena Blomstrand
Journal:  Ups J Med Sci       Date:  2021-05-12       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.